Viking stock doubled Tuesday. Here's where the next moves in

Anti-obesity drugmakers Novo Nordisk and Eli Lilly have a huge lead on their competition, but it's coming.

Related Keywords

United States , America , Yuri Khodjamirian , William Blair , Eli Lilly , Jeff Jonas , Novo Nordisk , Geoff Meacham , Tema Khodjamirian , Tema Etfs , Andy Hsieh , Zealand Pharma , Gabelli Jonas , Drug Administration , Becton Dickinson , Pfizer , Terns Pharmaceuticals , Mckesson , Centers For Disease , Astrazeneca , Disease Control , Viking Therapeutics , Tema Cardiovascular , Structure Therapeutics , Scholar Rock , Gabelli Funds , Becton Dickinson And Co , Merck Amp Co Inc , Biohaven Ltd , Pfizer Inc , Structure Therapeutics Inc , Altimmune Inc , Mckesson Corp , Regeneron Pharmaceuticals Inc , Astrazeneca Plc , Terns Pharmaceuticals Inc , Catalent Inc , Zealand Pharmaa S , Viking Therapeutics Inc , Eli Lilly And Co , Novo Nordiska S , Investment Strategy , Breaking News Investing , Health Care Industry , Biotech And Pharmaceuticals , Business News ,